A cost-benefit analysis of programmatic use of CVD 103-HgR live oral cholera vaccine in a high-risk population.

@article{Cookson1997ACA,
  title={A cost-benefit analysis of programmatic use of CVD 103-HgR live oral cholera vaccine in a high-risk population.},
  author={S. Cookson and D. Stamboulian and J. Demonte and L. Qu{\'e}ro and C. Martinez de Arquiza and A. Alem{\'a}n and A. Lepetic and M. Levine},
  journal={International journal of epidemiology},
  year={1997},
  volume={26 1},
  pages={
          212-9
        }
}
  • S. Cookson, D. Stamboulian, +5 authors M. Levine
  • Published 1997
  • Medicine
  • International journal of epidemiology
  • BACKGROUND Cholera spread to Latin America in 1991; subsequently, cholera vaccination was considered as an interim intervention until long-term solutions involving improved water supplies and sanitation could be introduced. Three successive summer cholera outbreaks in northern Argentina and the licensing of the new single-dose oral cholera vaccine, CVD 103-HgR, raised questions of the cost and benefit of using this new vaccine. METHODS This study explored the potential benefits to the… CONTINUE READING
    28 Citations
    Global economic evaluation of oral cholera vaccine: A systematic review
    • 5
    • Highly Influenced
    Costs of illness due to endemic cholera.
    • 25
    • PDF
    Private demand for cholera vaccines in Hue, Vietnam.
    • D. Kim, D. G. Canh, +10 authors D. Whittington
    • Economics, Medicine
    • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
    • 2008
    • 42
    • PDF
    WHO Position Paper on Cholera Vaccines
    • 2007
    • 5
    • PDF
    Evaluating Investments in Typhoid Vaccines in Two Slums in Kolkata, India
    • 21
    • PDF

    References

    SHOWING 1-10 OF 42 REFERENCES